Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Arisa Oki is active.

Publication


Featured researches published by Arisa Oki.


Biology of Blood and Marrow Transplantation | 2009

The Effect of Single and Combined Activating Killer Immunoglobulin-like Receptor Genotypes on Cytomegalovirus Infection and Immunity after Hematopoietic Cell Transplantation

John A. Zaia; J.Y. Sun; Ghislaine Gallez-Hawkins; Lia Thao; Arisa Oki; Simon F. Lacey; Andrew Dagis; Joycelynne Palmer; Don J. Diamond; Stephen J. Forman; David Senitzer

It has been shown that activating killer Ig-like receptor (aKIR) genes are important for control of cytomegalovirus (CMV) reactivation after hematopoietic cell transplantation (HCT). To date, using the broad classification of KIR haplotypes A and B, the precise role of individual KIR genes in the control of infection cannot be discerned. To address this, a consecutive case series of 211 non-T cell-depleted HCT patients all at risk for CMV were monitored biweekly for CMV DNA in plasma by quantitative polymerase chain reaction (Q-PCR) and at intervals for CMV-specific T cell immunity. Comparing patients with CMV reactivation (n = 152) to those with no reactivation (n = 59), the presence of specific aKIR haplotypes in the donor, but not in the recipient, were associated with protection from CMV reactivation and control of peak plasma CMV DNA (P < .001). A donor aKIR profile, predictive for low risk of CMV reactivation, contained either aKIR2DS2 and aKIR2DS4 or had >/=5 aKIR genes. Neither donor nor recipient inhibitory KIR (iKIR) played a role in a protective effect. CD4(+)- and CD8(+)-specific CMV immunity did not explain reduced CMV infection. The initial control of CMV infection after HCT is managed by aKIR functions, and donor aKIR haplotypes deserve further evaluation in donor selection for optimized HCT outcome.


Biology of Blood and Marrow Transplantation | 2011

Expression of Activating KIR2DS2 and KIR2DS4 Genes after Hematopoietic Cell Transplantation: Relevance to Cytomegalovirus Infection

Ghislaine Gallez-Hawkins; Anne E. Franck; Xiuli Li; Lia Thao; Arisa Oki; Ketevan Gendzekhadze; Andrew Dagis; Joycelynne Palmer; Ryotaro Nakamura; Stephen J. Forman; David Senitzer; John A. Zaia

The important role of activating killer immunoglobulin-like receptors (KIRs) in protecting against cytomegalovirus (CMV) reactivation has been described previously in patients undergoing hematopoietic cell transplantation (HCT). More specifically, the presence of multiple activating KIRs and the presence of at least KIR2DS2 and KIR2DS4 in the donor genotype identified a group of HCT patients at low risk for CMV reactivation. However, CMV infection still occurs in patients with the KIR protective genotype, and the question has been raised as to whether this is related to the lack of KIR expression. In this report, expression of the KIR2DS2 and KIR2DS4 genes, as measured by mRNA-based quantitative polymerase chain reaction in both the donor cells and the HCT recipient cells, was studied relative to CMV reactivation. In the control samples from healthy donors, the median range for KIR2DS2 and KIR2DS4 expression was low, with 35% of donors considered null-expressers. Interestingly, KIR2DS2 and KIR2DS4 expression was elevated after HCT compared with donor expression before HCT, and was significantly elevated in CMV viremic compared with CMV nonviremic HCT recipients. The CMV seropositivity of donors was not associated with activating KIR expression, and donor null expression in those with the KIR2DS2 or KIR2DS4 genotype was not predictive for CMV reactivation in the recipient. After controlling for other transplant factors, including donor type (sibling or unrelated), transplant source (bone marrow or peripheral blood stem cells), and acute GVHD grade, regression analysis of elevated KIR gene expression found an association for both KIR2DS2 and KIR2DS4, with a 7-fold increase in risk for CMV reactivation. We speculate that the elevated activating KIR expression in CMV-viremic HCT recipients is either coincidental with factors that activate CMV or is initiated by CMV or cellular processes responsive to such CMV infection reactivation.


Tissue Antigens | 2008

Alleles and intron polymorphism of KIR3DL1 shown by combination of allele group-specific primers and sequencing.

J.Y. Sun; Arisa Oki; David Senitzer

Allelic polymorphism of killer immunoglobulin-like receptor (KIR) genes may affect receptor expression as well as function. We used a combination of allele group-specific primers and DNA sequencing techniques to verify our KIR genotyping primers in polymerase chain reaction and identified three KIR3DL1 alleles. By sequencing some introns of 3DL1 in 18 genomic DNA samples, we found that a 4-bp insert in intron 1 of 3DL1*002 exists in multiple alleles, but that a 2-bp deletion in intron 7 is unique to 3DL1*01501 and that a 19-bp insert in intron 1 seems specific to the CEPH family 1416. Our data suggest that extensive KIR gene polymorphisms are ubiquitous as well as quite complex.


Human Immunology | 2017

P262 Dna sequencing with Scisco genetics next generation sequencing HLA typing version 5 kit

Arisa Oki; Randa Abou-Taleb; Jean Garcia-Gomez; Ketevan Gendzekhadze; David Senitzer


Biology of Blood and Marrow Transplantation | 2014

KIR Haplotype Assigment By Next Generation Sequencing

Ketevan Gendzekhadze; Lan-Feng Cao; Wyatt Nelson; Arisa Oki; Daniel E. Geraghty; David Senitzer


Human Immunology | 2012

125-P: QUANTITATIVE PCR CHIMERISM METHOD DETECTING MULTIPLE HSCT DONORS

Ketevan Gendzekhadze; Arisa Oki; David Senitzer


Biology of Blood and Marrow Transplantation | 2012

Is Kir Haplotype Matching Important

Ketevan Gendzekhadze; Arisa Oki; Y. Shen; Joycelynne Palmer; Auayporn Nademanee; Ryotaro Nakamura; Stephen J. Forman; David Senitzer


Human Immunology | 2009

13-W: Do anti-HLA antibodies impact hematopoietic stem cell transplantation (HSCT)?

Laima Gaidulis; Arisa Oki; Yvonne Zhou; Ketevan Gendzekhadze; David Senitzer


Biology of Blood and Marrow Transplantation | 2009

The Effect of Inhibitory Killer-Cell Ig-Like Receptor(iKIR) Matching in Allogeneic Hematopoietic Cell Transplantation(HCT)

David Senitzer; J.Y. Sun; Laima Gaidulis; Arisa Oki; A. Dagis; Joycelynne Palmer; Stephen J. Forman


Human Immunology | 2008

15-OR: The role of killer-cell Ig-like receptor (KIR) in hematopoietic cell transplantation (HCT) determined by overall alloimmune response

J.Y. Sun; Arisa Oki; A. Dagis; Laima Gaidulis; Stephen J. Forman; David Senitzer

Collaboration


Dive into the Arisa Oki's collaboration.

Top Co-Authors

Avatar

David Senitzer

City of Hope National Medical Center

View shared research outputs
Top Co-Authors

Avatar

J.Y. Sun

City of Hope National Medical Center

View shared research outputs
Top Co-Authors

Avatar

Stephen J. Forman

City of Hope National Medical Center

View shared research outputs
Top Co-Authors

Avatar

Ketevan Gendzekhadze

City of Hope National Medical Center

View shared research outputs
Top Co-Authors

Avatar

Laima Gaidulis

City of Hope National Medical Center

View shared research outputs
Top Co-Authors

Avatar

Joycelynne Palmer

City of Hope National Medical Center

View shared research outputs
Top Co-Authors

Avatar

A. Dagis

City of Hope National Medical Center

View shared research outputs
Top Co-Authors

Avatar

Andrew Dagis

City of Hope National Medical Center

View shared research outputs
Top Co-Authors

Avatar

Auayporn Nademanee

City of Hope National Medical Center

View shared research outputs
Top Co-Authors

Avatar

Ghislaine Gallez-Hawkins

City of Hope National Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge